Report

Comment: New Zealand talks tech September 2015

truScreen (TRU) manufactures and distributes a unique testing device that detects cancerous and pre-cancerous cells in the cervix. The developing world, which has the highest incidence and mortality from cervical cancer, is the target market. TRU, which listed on the NZX in November 2014, has secured China Food and Drug Administration (CFDA) approval to market TruScreen in China, where there is no cervical cancer testing regime and a potential market of 388 million.
Underlying
Truscreen

TruScreen Ltd. Truscreen Limited is a medical device company. The Company is engaged in the business of the development, manufacturing and sale of cancer detection devices and systems. Its Cervical Cancer Screening Device offers technology in cervical screening, providing real-time, accurate detection of precancerous and cancerous cervical cells to help improve the health and well-being of women worldwide. Its real-time cervical cancer technology utilizes a digital wand, which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated algorithm framework is utilized to detect pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue. The product offers an approach to cervical screening, resolving ongoing issues with Pap smear (Pap tests), including failed samples, patient follow-up, patient discomfort and the need for supporting laboratory infrastructure.

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch